SDRP Journal of Cellular and Molecular Physiology

ISSN: 2574-4046

VOLUME: 2 ISSUE: 1

THE ROLES OF MELATONIN IN PARKINSON’S DISEASE: AN OVERVIEW


Co-Authors

Xue Zhen Lim, Rhun Yian Koh, Khuen Yen Ng

Citation

Chye Soi Moi, THE ROLES OF MELATONIN IN PARKINSON’S DISEASE: AN OVERVIEW(2017)SDRP Journal of Cellular and Molecular Physiology 2(1)

Abstract

When the central nervous system loses its nerve cell functions over a period of time, symptoms and problems arise leading to the progression of neurodegenerative diseases. Statistical data shows that more than 5 million people worldwide are affected by Parkinson’s disease [PD], and the data is undesirably rising every year. In PD patients, structural and functional changes are shown in the brain, especially the substantia nigra region. The underlying cause that correspond to the development of PD remains unclear. Nevertheless, α-synuclein aggregation has been reported to be neuropathologically linked to PD. On the other hand, several evidences successfully demonstrate the importance and significance of mitochondrial dysfunction in PD models. Treatments available for PD are limited. Recently, as shown in some studies, the antioxidant properties and hypnotic benefits of melatonin bring remarkable contribution to the PD patients. Hence, in this article, we focus on the effect of melatonin associating with the pathology and physiology of PD.

Keywords: Antioxidant; Melatonin; Parkinson’s disease; Pathophysiology

References

  1. Schapira AH, Jenner P. Etiology and pathogenesis of Parkinson's disease. Mov Disord. 2011;26(6):1049-1055.

    View Article           

  2. Alexander GE. Biology of Parkinson's disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder. Dialogues Clin Neurosci. 2004;6(3):259-280.

  3. Bisaglia M, Soriano ME, Arduini I, Mammi S, Bubacco L. Molecular characterization of dopamine-derived quinones reactivity toward NADH and glutathione: implications for mitochondrial dysfunction in Parkinson disease. Biochim Biophys Acta. 2010 ;1802(9):699-706.

    View Article           

  4. Ojha S, Javed H, Azimullah S, Haque ME. ?-Caryophyllene, a phytocannabinoid attenuates oxidative stress, neuroinflammation, glial activation, and salvages dopaminergic neurons in a rat model of Parkinson disease. Mol Cell Biochem. 2016;418(1-2):59-70.

    View Article           

  5. Wu YR, Chen CM, Chao CY, Ro LS, Lyu RK, Chang KH, Lee-Chen GJ. Glucocerebrosidase gene mutation is a risk factor for early onset of Parkinson disease among Taiwanese. J Neurol Neurosurg Psychiatry. 2007;78(9):977-979.

    View Article           

  6. Henchcliffe C, Beal MF. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol. 2008;4(11):600-609.

    View Article           

  7. Nunomura A, Moreira PI, Lee HG, Zhu X, Castellani RJ, Smith MA, Perry G. Neuronal death and survival under oxidative stress in Alzheimer and Parkinson diseases. CNS Neurol Disord Drug Targets. 2007;6(6):411-423.

    View Article           

  8. Perfeito R, Cunha-Oliveira T, Rego AC. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse. Free Radic Biol Med. 2013;62:186-201.

    View Article           

  9. Tang G, Xie H, Xu L, Hao Y, Lin D, Ren D. Genetic study of apolipoprotein E gene, alpha-1 antichymotrypsin gene in sporadic Parkinson disease. Am J Med Genet. 2002 8;114(4):446-449.

  10. Ahn TB, Kim SY, Kim JY, Park SS, Lee DS, Min HJ, Kim YK, Kim SE, Kim JM, Kim HJ, Cho J, Jeon BS. Alpha-Synuclein gene duplication is present in sporadic Parkinson disease. Neurology. 2008;70(1):43-49.

    View Article           

  11. Ganesan M, Sathyaprabha TN, Pal PK, Gupta A. Partial body weight-supported treadmill training in patients with Parkinson disease: Impact on gait and clinical manifestation. Arch Phys Med Rehabil. 2015;96(9):1557-1565.

    View Article           

  12. Fuhr P, Maritz D, Bernatik J, Steck AJ. Initial symptomatology of Parkinson disease. Schweiz Arch Neurol Psychiatr. 1995;146(4):175-179.

  13. Gong Y, Xiong KP, Mao CJ, Shen Y, Hu WD, Huang JY, Han F, Chen R, Liu CF. Clinical manifestations of Parkinson disease and the onset of rapid eye movement sleep behavior disorder. Sleep Med. 2014;15(6):647-653.

    View Article           

  14. Zhang TM, Yu SY, Guo P, Du Y, Hu Y, Piao YS, Zuo LJ, Lian TH, Wang RD, Yu QJ, Jin Z, Zhang W. Nonmotor symptoms in patients with Parkinson disease: A cross-sectional observational study. Medicine (Baltimore). 2016;95(50):e5400.

    View Article           

  15. Schroeder LA, Rufra O, Sauvageot N, Fays F, Pieri V, Diederich NJ. Reduced rapid eye movement density in Parkinson disease: A polysomnography-based case-control study. Sleep. 2016;39(12):2133-2139.

    View Article           

  16. Gomperts SN. Lewy body dementias: dementia with Lewy bodies and Parkinson disease dementia. Continuum (Minneap Minn). 2016;22(2 Dementia):435-463.

  17. Fereshtehnejad SM, Romenets SR, Anang JB, Latreille V, Gagnon JF, Postuma RB. New clinical subtypes of Parkinson disease and their longitudinal progression: A prospective cohort comparison with other phenotypes. JAMA Neurol. 2015;72(8):863-873

    View Article           

  18. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670-1683.

    View Article           

  19. Williams WP, McLin DE, Dressman MA, Neubauer DN. Comparative review of approved melatonin agonists for the treatment of circadian rhythm sleep-wake disorders. Pharmacotherapy. 2016;36(9):1028-1041.

    View Article           

  20. Touitou Y, Smolensky MH, Reinberg A. Factors that can alter the melatonin circadian rhythm. Chronobiol Int. 2016;33(9):1129-1130.

    View Article           

  21. Flynn-Evans EE, Tabandeh H, Skene DJ, Lockley SW. Circadian rhythm disorders and melatonin production in 127 blind women with and without light perception. J Biol Rhythms. 2014;29(3):215-224.

    View Article           

  22. Korf HW, Schomerus C, Stehle JH. The pineal organ, its hormone melatonin, and the photoneuroendocrine system. Adv Anat Embryol Cell Biol. 1998;146:1-100.

    View Article           

  23. Young IM, Leone RM, Francis P, Stovell P, Silman RE. Melatonin is metabolized to N-acetyl serotonin and 6-hydroxymelatonin in man. J Clin Endocrinol Metab. 1985 ;60(1):114-9.

    View Article           

  24. Tenorio Fd, Sim?es Mde J, Teixeira VW, Teixeira ?A. Effects of melatonin and prolactin in reproduction: review of literature. Rev Assoc Med Bras (1992). 2015;61(3):269-274.

    View Article           

  25. Xin Z, Jiang S, Jiang P, Yan X, Fan C, Di S, Wu G, Yang Y, Reiter RJ, Ji G. Melatonin as a treatment for gastrointestinal cancer: a review. J Pineal Res. 2015;58(4):375-387.

    View Article           

  26. Abbas A, Raju J, Milles J, Ramachandran S. A circadian rhythm sleep disorder: melatonin resets the biological clock. J R Coll Physicians Edinb. 2010;40(4):311-313.

    View Article           

  27. Kuhn WF, Wellman A. The use of melatonin as a potential treatment for shiftwork sleep disorder. Acad Emerg Med. 1998;5(8):842-843.

    View Article           

  28. Bolitho SJ, Naismith SL, Rajaratnam SM, Grunstein RR, Hodges JR, Terpening Z, Rogers N, Lewis SJ. Disturbances in melatonin secretion and circadian sleep-wake regulation in Parkinson disease. Sleep Med. 2014;15(3):342-347.

    View Article           

  29. Lin L, Du Y, Yuan S, Shen J, Lin X, Zheng Z. Serum melatonin is an alternative index of Parkinson's disease severity. Brain Research. 2014;1547:43-48.

    View Article           

  30. Adi N, Mash D, Ali Y, Singer C, Shehadeh L, Papapetropoulos S. Melatonin MT1 and MT2 receptor expression in Parkinson's disease. Basic Res. 2010;16(2):61-67.

  31. Colin-Gonzalez AL, Aguilera G, Serratos IN, Escribano BM, Santamaria A, Tunez I. On the relationship between the light/dark cycle, melatonin and oxidative stress. Curr Pharm Des. 2015;21(24):3477-3488.

    View Article           

  32. Sol?s Herruzo JA, Sol?s Mu-oz P. Melatonin and oxidative stress. Rev Esp Enferm Dig. 2009;101(7):453-459

    View Article           

  33. Das A, Belagodu A, Reiter RJ, Ray SK, Banik NL. Cytoprotective effects of melatonin on C6 astroglial cells exposed to glutamate excitotoxicity and oxidative stress. J Pineal Res. 2008;45(2):117-124.

    View Article           

  34. Karbownik M, Lewi?ski A. Melatonin reduces Fenton reaction-induced lipid peroxidation in porcine thyroid tissue. J Cell Biochem. 2003;90(4):806-811.

    View Article           

  35. Br?mme HJ, M?rke W, Peschke E. Transformation of barbituric acid into alloxan by hydroxyl radicals: interaction with melatonin and with other hydroxyl radical scavengers. J Pineal Res. 2002;33(4):239-247.

    View Article           

  36. Ortiz GG, Pacheco-Mois?s FP, G?mez-Rodr?guez VM, Gonz?lez-Renovato ED, Torres-S?nchez ED, Ram?rez-Anguiano AC. Fish oil, melatonin and vitamin E attenuates midbrain cyclooxygenase-2 activity and oxidative stress after the administration of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine. Metab Brain Dis. 2013;28(4):705-709.

    View Article           

  37. Dabbeni-Sala F. Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity. The FASEB Journal. 2001;15(1):164-170.

    View Article           

  38. Mart?n V, Sainz RM, Antol?n I, Mayo JC, Herrera F, Rodr?guez C. Several antioxidant pathways are involved in astrocyte protection by melatonin. J Pineal Res. 2002;33(4):204-212.

    View Article           

  39. Santhanam S, Rajamanickam S, Motamarry A, Ramakrishna BS, Amirtharaj JG, Ramachandran A, Pulimood A, Venkatraman A. Mitochondrial electron transport chain complex dysfunction in the colonic mucosa in ulcerative colitis. Inflamm Bowel Dis. 2012 ;18(11):2158-68.

    View Article           

  40. Ganie SA, Dar TA, Bhat AH, Dar KB, Anees S, Zargar MA, Masood A. Melatonin: a potential anti-oxidant therapeutic agent for mitochondrial dysfunctions and related disorders. Rejuvenation Research. 2016;19(1):21-40.

    View Article           

  41. Chuang JI, Chen TH. Effect of melatonin on temporal changes of reactive oxygen species and glutathione after MPP(+) treatment in human astrocytoma U373MG cells. J Pineal Res. 2004;36(2):117-125.

    View Article           

  42. D?az-Casado ME, Lima E, Garc?a JA, Doerrier C, Aranda P, Sayed RK, Guerra-Librero A, Escames G, L?pez LC, Acu-a-Castroviejo D. Melatonin rescues zebrafish embryos from the parkinsonian phenotype restoring the parkin/PINK1/DJ-1/MUL1 network. J Pineal Res. 2016;61(1):96-107.

    View Article           

  43. Naskar A, Prabhakar V, Singh R, Dutta D, Mohanakumar KP. Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice. J Pineal Res. 2015;58(3):262-274.

    View Article           

  44. Zaitone SA, Hammad LN, Farag NE. Antioxidant potential of melatonin enhances the response to L-dopa in 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine-parkinsonian mice. Pharmacol Rep. 2013;65(5):1213-1226. 71479-8

    View Article           

  45. Mandal A, Hoop CL, DeLucia M, Kodali R, Kagan VE, Ahn J, van der Wel PC. Structural changes and proapoptotic peroxidase activity of cardiolipin-bound mitochondrial cytochrome c. Biophys J. 2015;109(9):1873-1484.

    View Article           

  46. Tapias V, Escames G, L?pez LC, L?pez A, Camacho E, Carri?n MD, Entrena A, Gallo MA, Espinosa A, Acu-a-Castroviejo D. Melatonin and its brain metabolite N(1)-acetyl-5-methoxykynuramine prevent mitochondrial nitric oxide synthase induction in parkinsonian mice. J Neurosci Res. 2009;87(13):3002-10.

    View Article           

  47. Escames G, L?pez LC, Tapias V, Utrilla P, Reiter RJ, Hitos AB, Le?n J, Rodr?guez MI, Acu-a-Castroviejo D. Melatonin counteracts inducible mitochondrial nitric oxide synthase-dependent mitochondrial dysfunction in skeletal muscle of septic mice. J Pineal Res. 2006;40(1):71-78.

    View Article           

  48. Pandi-Perumal SR, BaHammam AS, Brown GM, Spence DW, Bharti VK, Kaur C, Hardeland R, Cardinali DP. Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes. Neurotox Res. 2013;23(3):267-300.

    View Article           

  49. Sousa SC, Castilho RF. Protective effect of melatonin on rotenone plus Ca2+-induced mitochondrial oxidative stress and PC12 cell death. Antioxid Redox Signal. 2005;7(9-10):1110-1116.

    View Article           

  50. Breen DP, Vuono R, Nawarathna U, Fisher K, Shneerson JM, Reddy AB, Barker RA. Sleep and circadian rhythm regulation in early Parkinson disease. JAMA Neurol. 2014 ;71(5):589-595.

    View Article           

  51. Germain A, Kupfer DJ. Circadian rhythm disturbances in depression. Hum Psychopharmacol. 2008;23(7):571-585

    View Article           

  52. Azorin JM, Kaladjian A. Depression and circadian rhythm. Encephale. 2009;35 Suppl 2:S68-71. 75537-X

    View Article           

  53. Videnovic A, Noble C, Reid KJ, Peng J, Turek FW, Marconi A, Rademaker AW, Simuni T, Zadikoff C, Zee PC. Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease. JAMA Neurol. 2014;71(4):463-469

    View Article           

  54. Datieva VK, Rosinskaia AV, Levin OS. The use of melatonin in the treatment of chronic fatigue syndrome and circadian rhythm disorders in Parkinson's disease. Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(7 Pt 2):77-81.

  55. Ackermann K, Plomp R, Lao O, Middleton B, Revell VL, Skene DJ, Kayser M. Effect of sleep deprivation on rhythms of clock gene expression and melatonin in humans. Chronobiol Int. 2013;30(7):901-909.

    View Article           

  56. Hardeland R, Poeggeler B, Srinivasan V, Trakht I, Pandi-Perumal SR, Cardinali DP. Melatonergic drugs in clinical practice. Arzneimittelforschung. 2008;58(1):1-10.

  57. Zhang W, Chen XY, Su SW, Jia QZ, Ding T, Zhu ZN, Zhang T. Exogenous melatonin for sleep disorders in neurodegenerative diseases: a meta-analysis of randomized clinical trials. Neurol Sci. 2016;37(1):57-65.

    View Article           

  58. Barrenetxe J, Delagrange P, Mart?nez JA. Physiological and metabolic functions of melatonin. J Physiol Biochem. 2004;60(1):61-72.

    View Article           

  59. Liu Y, Tipoe GL, Fung ML. Melatonin attenuates intermittent hypoxia-induced lipid peroxidation and local inflammation in rat adrenal medulla. Int J Mol Sci. 2014;15(10):18437-18452.

    View Article           

  60. Ortiz GG, Crespo-L?pez ME, Mor?n-Moguel C, Garc?a JJ, Reiter RJ, Acu-a-Castroviejo D. Protective role of melatonin against MPTP-induced mouse brain cell DNA fragmentation and apoptosis in vivo. Neuro Endocrinol Lett. 2001;22(2):101-108.

  61. Mayo JC, Sainz RM, Uria H, Antolin I, Esteban MM, Rodriguez C. Melatonin prevents apoptosis induced by 6-hydroxydopamine in neuronal cells: implications for Parkinson's disease. J Pineal Res. 1998;24(3):179-92.

    View Article           

  62. Sousa SC, Castilho RF. Protective effect of melatonin on rotenone plus Ca2+-induced mitochondrial oxidative stress and PC12 cell death. Antioxid Redox Signal. 2005;7(9-10):1110-1116.

    View Article           

  63. Xue F, Shi C, Chen Q, Hang W, Xia L, Wu Y, Tao SZ, Zhou J, Shi A, Chen J. Melatonin mediates protective effects against Kainic acid-induced neuronal death through safeguarding ER stress and mitochondrial disturbance. Front Mol Neurosci. 2017; 10:49.

    View Article           

  64. Lin AM, Fang SF, Chao PL, Yang CH. Melatonin attenuates arsenite-induced apoptosis in rat brain: involvement of mitochondrial and endoplasmic reticulum pathways and aggregation of alpha-synuclein. J Pineal Res. 2007;43(2):163-171.

    View Article           

Journal Recent Articles